Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02DEZ
|
|||
| Former ID |
DIB015850
|
|||
| Drug Name |
GALE-301
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [1], [2], [3] | |
| Endometrial cancer [ICD-11: 2C76; ICD-9: 182] | Phase 1/2 | [4] | ||
| Company |
Galena biopharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035004) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.